Stock ENGN ENGENE HOLDINGS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company enGene Holdings Inc.

Equities

ENGN

CA29286M1059

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
 03:30:00 15/05/2024 am IST 		5-day change 1st Jan Change
13.62 USD -4.35% Intraday chart for enGene Holdings Inc. -4.29% +47.56%
15/05 EnGene Holdings Inc. Approves Board Appointments CI
22/04 Wells Fargo Starts enGene Holdings With Overweight Rating, $30 Price Target MT

Business Summary

enGene Holdings Inc. is a holding company. The Company, through its subsidiary, enGene Inc., is engaged in developing non-viral gene therapies based on localized delivery of nucleic acid payloads to mucosal tissues. The Company’s proprietary dually derived chitosan (DDX) platform has a high degree of payload flexibility, including DNA and various forms of RNA with broad tissue and disease application. In preclinical animal and in vitro models, the Company’s DDX technology has been demonstrated to effectively induce expression of therapeutic genes following delivery to the lung, gastrointestinal tract, and urinary tract, and its lead product detalimogene voraplasmid (EG-70) is being developed for the treatment of bacillus calmette-guerin (BCG)-resistant non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). EG-70 is a novel non-viral gene therapy designed to elicit a local immune response following the delivery to the bladder urothelium.

Number of employees: 32

Managers

Managers TitleAgeSince
Jason Hanson CEO
 Chief Executive Officer 55 08/23/08
Anthony Cheung FOU
 Founder 53 24/23/24
Alexander Nichols PSD
 President 38 01/11
Ryan Daws DFI
 Director of Finance/CFO 50 27/11
James Sullivan CTO
 Chief Tech/Sci/R&D Officer 45 01/11
Richard Bryce CTO
 Chief Tech/Sci/R&D Officer 66 01/11
lee Giguere LAW
 General Counsel 43 30/01

Members of the board

Members of the board TitleAgeSince
Lota Zoth BRD
 Director/Board Member 64 18/12
Jason Hanson CEO
 Chief Executive Officer 55 08/23/08
Gerry Brunk BRD
 Director/Board Member 55 08/23/08
Richard Glickman CHM
 Chairman 65 24/23/24
Jasper Bos BRD
 Director/Board Member 49 08/23/08

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 44,100,906 38,207,546 ( 86.64 %) 0 86.64 %

Shareholders

NameEquities%Valuation
Forbion Capital Partners Management Holding BV
19.69 %
8,677,951 19.69 % 128 M $
Lumira Capital Investment Management, Inc.
8.732 %
3,849,299 8.732 % 57 M $
Forbion Growth Sponsor Feac I B V
8.543 %
3,765,932 8.543 % 55 M $
Fonds de Solidarité FTQ
6.887 %
3,036,153 6.887 % 45 M $
Venrock Associates
5.820 %
2,565,841 5.820 % 38 M $
Foresite Capital Management LLC
5.671 %
2,500,000 5.671 % 37 M $
Blue Owl Healthcare Opportunities Advisors LLC
5.583 %
2,461,350 5.583 % 36 M $
BVF, Inc.
5.106 %
2,251,037 5.106 % 33 M $
BVF Partners LP
5.106 %
2,251,037 5.106 % 33 M $
Deep Track Capital LP
5.104 %
2,250,000 5.104 % 33 M $
NameEquities%Valuation
Forbion Capital Partners Management Holding BV
-
2,878,148 - 11 M $
BVF, Inc.
-
945,402 - 4 M $
Blue Owl Healthcare Opportunities Advisors LLC
-
511,177 - 2 M $
Omega Fund Management LLC
-
360,903 - 1 M $
Gritstone Asset Management LLC
-
224,501 - 873 309 $
Saba Capital Management LP
-
193,963 - 754 516 $
Calamos Advisors LLC
-
150,000 - 583 500 $
D.E. Shaw & Co., Inc.
-
104,622 - 406 980 $
Polar Asset Management Partners, Inc.
-
97,391 - 378 851 $
Atalaya Capital Management LP
-
66,666 - 259 331 $

Company contact information

enGene Holdings, Inc.

4868 Rue Levy Suite 220

H4R 2P1, Saint-Laurent

+

http://www.engene.com
address enGene Holdings Inc.(ENGN)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.98 USD
Average target price
34.4 USD
Spread / Average Target
+165.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ENGENE HOLDINGS INC. Stock enGene Holdings Inc.
+47.56% 57Cr
MODERNA, INC. Stock Moderna, Inc.
+33.63% 5.09TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 4.21TCr
LONZA GROUP AG Stock Lonza Group AG
+49.62% 4.2TCr
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 2.92TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 2.6TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 1.89TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 1.32TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 1.22TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 1.22TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ENGN Stock
  4. Company enGene Holdings Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW